Strattera Clinical Protocols
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Strattera Clinical Protocols
You may also be interested in...
Lilly Strattera Long-Term Efficacy Studies To Be Completed In 2003
Lilly expects to complete two postmarketing studies assessing long-term efficacy of its attention deficit/hyperactivity disorder drug Strattera by the end of 2003.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product